Update on Hydroxychloroquine:
The latest study finds no benefit from hydroxychloroquine. Hydroxycholorquine was heralded as a potential game-changer for treating COVID-19. However, a new study shows that the drug is of little benefit. This does not mean it should be written off as a potential treatment option. It has shown antiviral activity in-vitro and the rationale for its use is plausible. More evidence is still needed and clinical trials are still ongoing.
- Tang W, Cao Z, Han M, et al. Hydroxychloroquine in Patients with COVID-19: An Open-Label, Randomized, Controlled Trial. Infectious Diseases (except HIV/AIDS); 2020. doi:10.1101/2020.04.10.20060558
- Ornstein MH, Sperber K. The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Arthritis Rheum. 1996;39(1):157-161. doi:10.1002/art.1780390122